Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model.

Autor: Kempster S; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK. Electronic address: sarah.kempster@mhra.gov.uk., Hassall M; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK., Graham V; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK., Kennedy E; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK., Findlay-Wilson S; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK., Salguero FJ; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK., Bagci B; Sivas Cumhuriyet University, Sivas, Turkey., Elaldi N; Sivas Cumhuriyet University, Sivas, Turkey., Oz M; Sivas Cumhuriyet University, Sivas, Turkey., Tasseten T; Sivas Cumhuriyet University, Sivas, Turkey., Charlton FW; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK; Astbury Centre, Astbury Centre for Structural Molecular Biology, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK; Current address: Supramolecular nanomaterials and interfaces laboratory (SuNMIL), École Polytechnique Fédérale de Lausanne, Switzerland., Barr JN; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK; Astbury Centre, Astbury Centre for Structural Molecular Biology, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK., Fontana J; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK; Astbury Centre, Astbury Centre for Structural Molecular Biology, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK., Duru C; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK., Ezeajughi E; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK., Matejtschuk P; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK., Arnold U; High Containment Microbiology and Imaging, UKHSA, 61 Colindale Avenue, London, NW9 5EQ, UK., Adedeji Y; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK., Mirazimi A; Public Health Agency of Sweden, Solna, Sweden; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, ANA Futura, Campus Flemingsberg, Stockholm, Sweden., Hewson R; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom., Dowall S; Virology & Pathogenesis group, UK Health Security Agency, Manor Farm Rd, Porton Down, Salisbury SP4 0JG, UK., Almond N; Science Research and Innovation, Medicines and Healthcare products Regulatory Agency, Blanche Lane, South Mimms, EN6 3QG, UK.
Jazyk: angličtina
Zdroj: Virus research [Virus Res] 2024 Aug; Vol. 346, pp. 199409. Date of Electronic Publication: 2024 Jun 01.
DOI: 10.1016/j.virusres.2024.199409
Abstrakt: Crimean-Congo Haemorrhagic Fever Virus (CCHFV) is spread by infected ticks or direct contact with blood, tissues and fluids from infected patients or livestock. Infection with CCHFV causes severe haemorrhagic fever in humans which is fatal in up to 83 % of cases. CCHFV is listed as a priority pathogen by the World Health Organization (WHO) and there are currently no widely-approved vaccines. Defining a serological correlate of protection against CCHFV infection would support the development of vaccines by providing a 'target threshold' for pre-clinical and clinical immunogenicity studies to achieve in subjects and potentially obviate the need for in vivo protection studies. We therefore sought to establish titratable protection against CCHFV using pooled human convalescent plasma, in a mouse model. Convalescent plasma collected from seven individuals with a known previous CCHFV virus infection were characterised using binding antibody and neutralisation assays. All plasma recognised nucleoprotein and the Gc glycoprotein, but some had a lower Gn glycoprotein response by ELISA. Pooled plasma and two individual donations from convalescent donors were administered intraperitoneally to A129 mice 24 h prior to intradermal challenge with CCHFV (strain IbAr10200). A partial protective effect was observed with all three convalescent plasmas characterised by longer survival post-challenge and reduced clinical score. These protective responses were titratable. Further characterisation of the serological reactivities within these samples will establish their value as reference materials to support assay harmonisation and accelerate vaccine development for CCHFV.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Crown Copyright © 2024. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: